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論文の内容の要旨 
Abstract of thesis 
 
In this thesis, Ms. NGO THAI BICH VAN described the role of the phospholipid-metabolizing enzyme 
Phospholipase D2 in anti-tumor immunity. The abstract is as follows: 
 
【材料と方法 Materials and Methods】 
The applicant subcutaneously transplanted cancer cells into wild-type and Pld2-knockout mice to form 
tumors and analyzes tumor-infiltrating CD4+ and CD8+ cells by immunostaining. She also analyzed T cell 
population in the thymus and spleen by flow cytometry and applied bone marrow transplantation to investigate the 
effects of PLD2 on immune cells. In vitro proliferation of primary CD8+ T cells under co-stimulation of 
CD3/CD28 is examined by using Carboxyfluorescein succinimidyl ester (CFSE) assay. CD3/CD28-dependent 
phosphorylation of Erk in primary CD8+ T cells is also analyzed by Western blot analysis. Ras activation was 
detected by pull-down assay. 
 
【結果 Results】 
The applicant found that the growth of the tumor formed by subcutaneously transplanted cancer cells was 
enhanced in Pld2-/- mice. Unlike PLD1, PLD2 was dispensable for tumor angiogenesis in mice. In line with the 
increase of tumor size, cell apoptosis was inhibited in tumors formed in Pld2-/- mice. The result of bone marrow 
transplantation indicated that PLD2 in bone marrow- derived cells showed a suppressive function in tumor growth. 
-２ 
Thus, the applicant examined the function of PLD2 in T lymphocytes as they were the major components of 
adaptive immunity, being recruited into the tumor microenvironment together with other immune cells to 
eliminate tumor cells. Interestingly, the number of CD8+ T cells, which are known to induce cancer cell death, was 
significantly decreased in Pld2-/- tumor sections. In addition, CD3/CD28-stimulated proliferation of primary 
cultured CD8+ T cells isolated from the Pld2-/- spleen was significantly suppressed compared to that of WT CD8+ 
T cells. On the other hand, no significant difference was seen in proliferation between WT and Pld2-/- CD4+ T cells. 
Furthermore, CD3/CD28-dependent phosphorylation of Erk1/2 and Ras activation were inhibited in Pld2-/- CD8+ 
T cells. Production of Interleukin-2 (IL-2), one of the downstream target gene of Erk, which is known to promote 
CD8+ T cell proliferation, was also decreased in Pld2-/- CD8+ T cells.  
 
【考察 Discussion】 
Previous reports provided evidences for the central role of CD8+ T cells in anti-tumor immunity and are 
consistent with the notion that impaired CD8+ T cell infiltration into tumor microenvironment in Pld2-/- mice 
promoted tumor growth. In the present study, the applicant focused on the function of PLD2 in CD4+ and CD8+ T 
cells. In dissecting the signaling pathway involved in PLD2-mediated T cell proliferation, she found that PLD2 wa 
required for CD3/CD28-stimulated Ras activation and Erk phosphorylation in primary CD8+ T cells. Other reports 
showed that PLD2 can activate Ras through the action of RasGEF. Taken together, it was reasonable to speculate 
that, upon TCR engagement of CD8+ T cells, PLD2 recruits a Ras GEF to the specific compartment such as the 
plasma membrane, inducing compartmentalized and temporal activation of Ras-Erk signaling to promote cell 
proliferation and survival.  
 
審査の結果の要旨 
Abstract of assessment result 
 
【批評 General Comments】 
The applicant provided evidence that PLD2 promotes CD8+ T cell proliferation upon TCR engagement in the 
spleen through the activation of Ras-Erk pathway and IL-2 production, thereby potentiating the anti-tumor 
immune response. The findings revealed a novel function of PLD2 in the immune system, which may contribute 
to eliminate cancer cells. 
 
【最終試験の結果 Assessment】 
The final examination committee conducted a meeting as a final examination on June 5, 2017. The applicant 
provided an overview of dissertation, addressed questions and comments raised during Q&A session. All of the 
committee members reached a final decision that the applicant has passed the final examination. 
 
【結果 Conclusion】 
Therefore, the final examination committee approved that the applicant is qualified to be awarded Doctor of 
Philosophy in Medical Sciences. 
 
 
 
